Australian entrepreneur Paul Conyngham has unveiled a groundbreaking AI-driven approach to designing a personalized mRNA cancer vaccine for his pet dog. Diagnosed with a malignant mast cell tumor in May 2024, the dog underwent whole-genome and RNA sequencing, generating 300 GB of genetic data. Conyngham's team utilized AI chatbots, including ChatGPT, Gemini, and Grok, to conduct target screening and protein structure modeling, identifying a c-KIT gene mutation and selecting seven novel antigen targets. The vaccine, developed in collaboration with the University of New South Wales and administered by the University of Queensland's School of Veterinary Science, was part of a comprehensive treatment plan. This included a tyrosine kinase inhibitor and a PD-1 inhibitor, with dosing optimized through AI. Three months post-treatment, some tumors reduced in size, though surgical intervention was needed for non-responsive lesions. Experts caution that this case is not a generalizable medical conclusion.